BrightGene Bio Medical Technology C (688166) — Cash Flow Quality Index
BrightGene Bio Medical Technology C (688166) has a Cash Flow Quality Index of 0.69x as of June 2023. Operating cash flow of CN¥26.70 Million is below net income of CN¥38.67 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how efficiently does BrightGene Bio Medical Technology C generate cash to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
BrightGene Bio Medical Technology C Cash Flow Quality Index (2016–2024)
Historical Cash Flow Quality Index for BrightGene Bio Medical Technology C across 9 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 688166 cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for BrightGene Bio Medical Technology C (2016–2024)
Year-by-year earnings quality comparison for BrightGene Bio Medical Technology C. For live market cap and the full company financial profile, see BrightGene Bio Medical Technology C market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.30x | CN¥245.56 Million | CN¥189.17 Million | ▲ +33.7% |
| 2023 | 0.97x | CN¥194.77 Million | CN¥200.58 Million | ▼ -25.2% |
| 2022 | 1.30x | CN¥311.26 Million | CN¥239.62 Million | ▲ +79.8% |
| 2021 | 0.72x | CN¥176.08 Million | CN¥243.74 Million | ▼ -21.0% |
| 2020 | 0.91x | CN¥155.43 Million | CN¥170.08 Million | ▲ +65.5% |
| 2019 | 0.55x | CN¥61.33 Million | CN¥111.08 Million | ▼ -36.8% |
| 2018 | 0.87x | CN¥63.99 Million | CN¥73.20 Million | ▲ +12.1% |
| 2017 | 0.78x | CN¥35.77 Million | CN¥45.88 Million | ▼ -55.3% |
| 2016 | 1.74x | CN¥29.73 Million | CN¥17.06 Million | — |